HOUSTON, March 4, 2026 /PRNewswire/ -- The World Health Organization (WHO) has announced its recommendations for the 2026-2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A(H3N2) subclade K and emerging B/Victoria lineage strains. In rapid response, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has launched the 2026-2027 Northern Hemisphere influenza vaccine strain antigens to accelerate vaccine development.

Decoding the 2026-2027 Northern Hemisphere Influenza Vaccine Strains

Since its identification in August 2025, H3N2 subclade K (J.2.4.1) has become the dominant influenza A strain globally. Defined by the T135K and S144N mutations, this strain exhibits enhanced immune escape, prompting WHO to select A/Darwin/1454/2025 as the new H3N2 reference virus. The H1N1 component has been updated to A/Missouri/11/2025. Meanwhile, B/Victoria lineage activity is rising sharply, with proportions increasing from 6% to over 20% in regions including Hong Kong SAR and the U.S., leading WHO to recommend B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains.

Sino Biological's Comprehensive Reagents for Influenza Research

To support global influenza vaccine research and development, Sino Biological has launched an extensive portfolio of recombinant antigens for the 2026-2027 influenza vaccine strains, including A/Missouri/11/2025 (H1N1) HA Trimer (purity ≥90% verified by SEC-MALS), NA, and NP proteins. "Our mission is to provide the scientific community with the highest quality tools as rapidly as possible when infectious disease evolution threatens global health preparedness," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US.

About Sino Biological

Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in more than 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or partnership opportunities, please contact:

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com

View original content:https://www.prnewswire.co.uk/news-releases/advancing-influenza-vaccine-development-sino-biological-launches-antigens-for-the-2026-2027-northern-hemisphere-influenza-vaccine-strains-302703311.html

Tags

More Like This

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu

Sinovac Amends Shareholder Rights Plan

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

INNORNA Completes Phase II Enrollment and Vaccination of Bivalent RSV mRNA Vaccine IN006

Hansa Biopharma Interim Report January-September 2023

Hansa Biopharma publishes 2023 Annual and Sustainability Reports